MedPath
HSA Approval

DIFFORAL CAPSULES 250MG

SIN16932P

DIFFORAL CAPSULES 250MG

DIFFORAL CAPSULES 250MG

January 17, 2024

GOLDPLUS UNIVERSAL PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantGOLDPLUS UNIVERSAL PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

CAPSULE

ORAL

Medical Information

A07AA09

vancomycin

Manufacturer Information

GOLDPLUS UNIVERSAL PTE LTD

Kleva Pharmaceuticals S.A.

Active Ingredients

Vancomycin Hydrochloride eqv Vancomycin

250 mg

Vancomycin

Documents

Package Inserts

Difforal Capsule PI.pdf

Approved: January 17, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

DIFFORAL CAPSULES 250MG - HSA Approval | MedPath